USA - Washington

Director of Policy and External Affairs Justin Nordhorn discussed the background, intent, and changes requested in draft legislation on “psychotropic” and “impairing” cannabis compounds.

Industry, academic, and agency representatives brought lawmakers up to speed on CBD product research and policy development in Washington state.

WSLCB staff would attempt to clarify their intent to reform cannabis law in Washington state, while CANNRA leaders educated public health and prevention practitioners on similar subjects.

Three recommendations for the 2022 legislative session were put forward by the licensing work group and adopted by the task force following discussion and amendment.

Board members adopted rules on importation of CBD products for use as additives - but would soon have to approve an interim policy creating an exemption from traceability requirements.

The social equity licensing work group would learn about “Social Consumption Lounges” and the Cannabis Alliance planned to host state officials to discuss crucial contemporary topics.

The board began rescinding unnecessary interim policies, heard rulemaking updates, and a licensee called for more time to transition from seed-to-sale traceability to weekly reporting.

A single patient offered testimony recommending sales tax breaks be reserved for registered patient purchases of DOH compliant products to incentivize “medical grade” production.

A public hearing on the implementation of imported CBD rules drew suggested revisions on cannabis product testing standards from the public and a WSDA pesticide official.

The social equity task force was scheduled to review significant legislative proposals developed by work group members, and WSDA opened its pesticide penalty regime for revision.